TORONTO, ONTARIO – Established medical electrocardiogram (“ECG”) software and device manufacturer CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), today announced it has received the ACQ5 award as the Niche Technology Company of the Year in the Healthcare and Telemedicine category. The ACQ5 2017 award is sponsored by Acquisition Finance which is published under license from the Metropolis International Group Ltd. The magazine is circulated to CEO’s and CFO’s as well as other corporate finance and private equity executives globally.

The 12th ACQ5 Global Awards focus on organisations that demonstrate an ability to deliver services and skills to meet clients’ needs and who can adapt to changing market and regulatory conditions. The ACQ5 Global Awards winners are peer nominated and the award winner categories published in the Acquisition Finance magazine is circulated to 163,000 senior executives. The publication reviews the driving forces in various industries examines sector characteristics to provide information that supports M&A activity and foreign direct investment including information on investors, buyers and sellers.

CardioComm Solutions’ award is based on demonstrated leadership, innovation and momentum in influencing the telemedicine and healthcare markets. The award recognizes CardioComm Solutions as a collaborator in clinical research, R&D projects with start-ups and academic groups as a facilitator in providing “software as a medical device” partnerships to help disruptive medical technologies see market readiness with reduced cycle times. The Company efforts in this regard have been confirmed by recent announcements of partnerships with companies active in the telemedicine markets and by other awards, such as the recently announced Best In Medical Software Development for 2017.

CardioComm Solutions plans to continue growing their recognition as a credible m-health and consumer wellness technologies provider and has implemented a strategy of expanding the licensed use of its well-developed ECG connectivity and management technologies as “back office” medical software to their partners and customers. Despite the diagnostic value of ECG monitoring, telemedicine platforms have not previously included ECG monitoring due to the existing complexity of device integration and associated regulatory controls. The Company believes 2018 will be a period when increasing regulatory and performance pressure will be placed on North American healthcare and telemedicine providers to develop better and updated healthcare platforms to support more comprehensive health monitoring capabilities. Specifically, CardioComm Solutions will benefit from the need of these providers to look to the use of credible and proven software controls and monitoring devices that can meet the performance and use expectations of a health authority approved medical device system. The ACQ5 Award also acknowledges that the Company pipeline of technologies will meet the unmet needs for enhanced data collection in telemedicine platforms. This is expected to push the boundaries for access to credible data, not just ECGs but other biosigns, for use in predictive analysis.

CardioComm Solutions will be providing further updates regarding their medical and consumer ECG recording technologies and award updates. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances for the sale of the HeartCheck™ technologies from the European Union (CE Mark), the USA (FDA), China (CFDA) and Canada (Health Canada). To learn more about the CardioComm Solutions’ products, please see the Company’s websites and